Takara Bio Inc. (FRA:TF2)
Germany · Delayed Price · Currency is EUR 4.260
+0.120 (2.90%)
At close: Nov 21, 2025
Takara Bio Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 44,075 | 45,039 | 43,505 | 78,142 | 67,699 | 46,086 | Upgrade | |
Revenue Growth (YoY) | -0.16% | 3.53% | -44.33% | 15.43% | 46.90% | 33.33% | Upgrade |
Cost of Revenue | 19,889 | 18,972 | 16,597 | 33,377 | 18,488 | 14,214 | Upgrade |
Gross Profit | 24,186 | 26,067 | 26,908 | 44,765 | 49,211 | 31,872 | Upgrade |
Selling, General & Admin | 17,850 | 16,901 | 15,615 | 15,570 | 14,180 | 12,357 | Upgrade |
Research & Development | 6,913 | 6,897 | 8,324 | 8,575 | 6,109 | 5,545 | Upgrade |
Operating Expenses | 24,683 | 23,804 | 23,905 | 24,224 | 20,309 | 17,919 | Upgrade |
Operating Income | -497 | 2,263 | 3,003 | 20,541 | 28,902 | 13,953 | Upgrade |
Interest Expense | -253 | -20 | -23 | -24 | -23 | -24 | Upgrade |
Interest & Investment Income | 243 | 300 | 186 | 142 | 122 | 113 | Upgrade |
Currency Exchange Gain (Loss) | -34 | -131 | 97 | -120 | -706 | 2 | Upgrade |
Other Non Operating Income (Expenses) | 97 | 179 | 140 | 142 | 163 | 115 | Upgrade |
EBT Excluding Unusual Items | -444 | 2,591 | 3,403 | 20,681 | 28,458 | 14,159 | Upgrade |
Gain (Loss) on Sale of Investments | -84 | -84 | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | -118 | -135 | -344 | -97 | -168 | -98 | Upgrade |
Asset Writedown | -4,139 | -377 | -207 | - | -5,227 | -517 | Upgrade |
Other Unusual Items | 30 | 1 | - | 639 | 4,468 | 8 | Upgrade |
Pretax Income | -4,755 | 1,996 | 2,852 | 21,223 | 27,531 | 13,552 | Upgrade |
Income Tax Expense | 1,580 | 910 | 1,343 | 5,176 | 7,624 | 3,971 | Upgrade |
Earnings From Continuing Operations | -6,335 | 1,086 | 1,509 | 16,047 | 19,907 | 9,581 | Upgrade |
Minority Interest in Earnings | -48 | -45 | -29 | -35 | -58 | -34 | Upgrade |
Net Income | -6,383 | 1,041 | 1,480 | 16,012 | 19,849 | 9,547 | Upgrade |
Net Income to Common | -6,383 | 1,041 | 1,480 | 16,012 | 19,849 | 9,547 | Upgrade |
Net Income Growth | - | -29.66% | -90.76% | -19.33% | 107.91% | 149.99% | Upgrade |
Shares Outstanding (Basic) | 120 | 120 | 120 | 120 | 120 | 120 | Upgrade |
Shares Outstanding (Diluted) | 120 | 120 | 120 | 120 | 120 | 120 | Upgrade |
EPS (Basic) | -53.01 | 8.65 | 12.29 | 132.97 | 164.84 | 79.28 | Upgrade |
EPS (Diluted) | -53.01 | 8.65 | 12.29 | 132.97 | 164.84 | 79.28 | Upgrade |
EPS Growth | - | -29.66% | -90.76% | -19.33% | 107.91% | 149.99% | Upgrade |
Free Cash Flow | -18,345 | -4,027 | -11,067 | 31,150 | -5,418 | 5,256 | Upgrade |
Free Cash Flow Per Share | -152.35 | -33.44 | -91.91 | 258.69 | -44.99 | 43.65 | Upgrade |
Dividend Per Share | 17.000 | 17.000 | 17.000 | 42.000 | 33.000 | 16.000 | Upgrade |
Dividend Growth | - | - | -59.52% | 27.27% | 106.25% | 100.00% | Upgrade |
Gross Margin | 54.87% | 57.88% | 61.85% | 57.29% | 72.69% | 69.16% | Upgrade |
Operating Margin | -1.13% | 5.03% | 6.90% | 26.29% | 42.69% | 30.28% | Upgrade |
Profit Margin | -14.48% | 2.31% | 3.40% | 20.49% | 29.32% | 20.72% | Upgrade |
Free Cash Flow Margin | -41.62% | -8.94% | -25.44% | 39.86% | -8.00% | 11.40% | Upgrade |
EBITDA | 4,410 | 6,744 | 8,024 | 25,276 | 33,051 | 17,739 | Upgrade |
EBITDA Margin | 10.01% | 14.97% | 18.44% | 32.35% | 48.82% | 38.49% | Upgrade |
D&A For EBITDA | 4,907 | 4,481 | 5,021 | 4,735 | 4,149 | 3,786 | Upgrade |
EBIT | -497 | 2,263 | 3,003 | 20,541 | 28,902 | 13,953 | Upgrade |
EBIT Margin | -1.13% | 5.03% | 6.90% | 26.29% | 42.69% | 30.28% | Upgrade |
Effective Tax Rate | - | 45.59% | 47.09% | 24.39% | 27.69% | 29.30% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.